Paediatric Antiretroviral Update

Overview

Journal South Afr J HIV Med

Specialty Infectious Diseases

Date 2023 Dec 13

PMID 38089886

Authors

Gillian Sorour

Nosisa Sipambo

Moherndran Archary

Affiliations

Soon will be listed here.

Citing Articles

95-95-95 HIV indicators among children younger than 15 years in South Africa: results from the 2017 national HIV prevalence, incidence, behaviour, and communication survey.

Magobo R, Mabaso M, Jooste S, Molopa L, Naidoo I, Simbayi L AIDS Res Ther. 2025; 22(1):6.

PMID: 39810159 PMC: 11731543. DOI: 10.1186/s12981-024-00691-8.

Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis.

Brenner I, Flanagan C, Penazzato M, Webb K, Horsfall S, Hyle E Lancet Glob Health. 2024; 12(12):e2068-e2079.

PMID: 39577977 PMC: 11584319. DOI: 10.1016/S2214-109X(24)00381-4.

References

Bacha J, Dlamini S, Anabwani F, Gwimile J, Kanywa J, Farirai J . Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023; 42(7):576-581. PMC: 10259212. DOI: 10.1097/INF.0000000000003878. View

Cevik M, Orkin C, Sax P . Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases. Open Forum Infect Dis. 2020; 7(6):ofaa202. PMC: 7304932. DOI: 10.1093/ofid/ofaa202. View

Bollen P, Moore C, Mujuru H, Makumbi S, Kekitiinwa A, Kaudha E . Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Lancet HIV. 2020; 7(8):e533-e544. PMC: 7445428. DOI: 10.1016/S2352-3018(20)30189-2. View

Turkova A, White E, Mujuru H, Kekitiinwa A, Kityo C, Violari A . Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021; 385(27):2531-2543. PMC: 7614690. DOI: 10.1056/NEJMoa2108793. View

Archary M, Van Zyl R, Sipambo N, Sorour G . Optimised paediatric antiretroviral treatment to achieve the 95-95-95 goals. South Afr J HIV Med. 2021; 22(1):1278. PMC: 8517773. DOI: 10.4102/sajhivmed.v22i1.1278. View

Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh J . Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. Lancet HIV. 2022; 9(8):e544-e553. DOI: 10.1016/S2352-3018(22)00136-9. View

Ruel T, Acosta E, Liu J, Gray K, George K, Montanez N . Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. Lancet HIV. 2022; 9(5):e332-e340. PMC: 9313528. DOI: 10.1016/S2352-3018(22)00044-3. View

Molina J, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K . Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015; 2(4):e127-36. DOI: 10.1016/S2352-3018(15)00027-2. View

Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo J, Mamedova E . Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019; 19(3):253-264. DOI: 10.1016/S1473-3099(19)30036-2. View

10.

Waalewijn H, Chan M, Bollen P, Mujuru H, Makumbi S, Kekitiinwa A . Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022; 9(5):e341-e352. PMC: 9046096. DOI: 10.1016/S2352-3018(21)00292-7. View